54 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
in the course of exercising the rights granted under the Licence and Exploiting Licensed Products, including any Patents that claim any Materials or inventions … described or comprised in Know How or Materials, with the exception of Licensee’s trade secrets and other proprietary information previously known
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
for the manufacture of materials and expects to continue to do so for its clinical trials and for commercialization of TNT119. This reliance on third parties … increases the risk that Tenet will not have sufficient quantities of such materials or that such supply will not be available to Tenet
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, including applicable annexes and (ii) the FD&C Act and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical materials
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
) the tangible assets of Seller that solely and specifically relate to the Business, including any materials, assays or manufacturing runs, and that are set … retained by Seller, (E) personnel notes, and (F) all privileged materials not transferred to Buyer;
(iii) all cash and cash equivalents;
(iv) all
8-K
EX-99.5
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research … Agreement”). The CRH Agreement granted the Company a worldwide exclusive license (other than specified patent rights and materials, which are licensed
8-K
97oj9tju1 0siypdcwsa
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.4
bxoq lru9
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
tur2w0xlehnner
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
DEFA14A
1fu209 40
14 Jun 24
Additional proxy soliciting materials
5:02pm
DEFA14A
49c8nvuzd
12 Jun 24
Additional proxy soliciting materials
4:42pm
8-K
EX-10.1
adgs8i
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
2gixoog9hb
4 Jun 24
Proxy related to merger
8:00am
PREM14A
y4byvk
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
j1oivw8
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
i70o8
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.2
a5vd pbi18jpsjx3v
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am